SOUTH SAN FRANCISCO, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics ...

Gilead Sciences Inc. recently discussed the discovery of emvistegrast (GS-1427), a potent, selective, once-daily oral α4β7 integrin inhibitor currently in phase II trials for the treatment of ...

The ability of cells to migrate is essential to many processes during development and homeostasis but is also essential for cancer progression. Cell attachment to the extracellular matrix (ECM) is ...

Panelists discuss several promising new agents for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), including an LPA1 receptor antagonist showing lung function ...

C4X Discovery Holdings Ltd. has selected a preclinical candidate from its oral α4β7 integrin inhibitor program for the treatment of inflammatory bowel disease (IBD). The potent and selective α4β7 ...

Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant ...

Integrins are heterodimeric transmembrane receptors that mediate adhesion to the extracellular matrix and engage bidirectional signalling across the plasma membrane. Activation is controlled by ...

Multidisciplinary Oncology Center, University of Lausanne Hospitals, and the Swiss Institute for Experimental Cancer Research, National Center of Competence in Research Molecular Oncology, Epalinges, ...

Eli Lilly has agreed to acquire Morphic Therapeutic for approximately $3.2 billion, the companies said today, in a deal designed to bolster the buyer’s pipeline with chronic disease candidates led by ...

Most inflammatory bowel disease (IBD) therapies — particularly biologic agents — appear safe in patients with chronic kidney disease (CKD); however, caution is required with certain conventional ...